Literature DB >> 24227845

A cell-biased effect of estrogen in prion infection.

Brendan Molloy1, Hilary E M McMahon.   

Abstract

Prion disorders are associated with the accumulation of a misfolded form (PrP(Sc)) of the normal prion protein, PrP(C). Here, we show that estrogen acts as a regulator of the processes of both prion infection and prion maintenance. Estrogen was found to be cell biased in its effect; it protected cells against prion infection in a prevention mode and enabled prion maintenance in a treatment mode. These processes were regulated by the estrogen receptor subtypes Erα and Erβ. By using specific receptor agonists, Erα was found to be the main receptor active in slowing prion infection, whereas in chronically infected cells, although Erα allowed partial maintenance of PrP(Sc) levels, Erβ was the main receptor involved in maintaining PrP(Sc) in a treatment paradigm. A cell-biased effect of estrogen has been reported for other neurodegenerative disorders, including Alzheimer's disease. Estrogen's effect is dependent on the cell's health status, which impacts the use of estrogen. This work also identified that by targeting the estrogen receptors with the selective estrogen receptor modulators tamoxifen (Tam) and 4-hydroxy-tamoxifen (OHT), PrP(Sc) could be cleared from prion-infected cell culture. Tam and OHT had half-maximal inhibitory concentrations for clearance of PrP(Sc) of 0.47 μM and 0.14 nM, respectively. This work identifies further factors involved in the prion disease process, and through antagonism of the estrogen system, we demonstrate that the estrogen system is a target for controlling PrP(Sc) levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24227845      PMCID: PMC3911640          DOI: 10.1128/JVI.02936-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein.

Authors:  N Nishida; D A Harris; D Vilette; H Laude; Y Frobert; J Grassi; D Casanova; O Milhavet; S Lehmann
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists.

Authors:  S R Stauffer; C J Coletta; R Tedesco; G Nishiguchi; K Carlson; J Sun; B S Katzenellenbogen; J A Katzenellenbogen
Journal:  J Med Chem       Date:  2000-12-28       Impact factor: 7.446

3.  Dose and temporal pattern of estrogen exposure determines neuroprotective outcome in hippocampal neurons: therapeutic implications.

Authors:  Shuhua Chen; Jon Nilsen; Roberta Diaz Brinton
Journal:  Endocrinology       Date:  2006-08-17       Impact factor: 4.736

Review 4.  Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications.

Authors:  Darrell W Brann; Krishnan Dhandapani; Chandramohan Wakade; Virendra B Mahesh; Mohammad M Khan
Journal:  Steroids       Date:  2007-02-21       Impact factor: 2.668

Review 5.  Estrogen receptors: therapies targeted to receptor subtypes.

Authors:  S Nilsson; J-Å Gustafsson
Journal:  Clin Pharmacol Ther       Date:  2010-12-01       Impact factor: 6.875

6.  C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection.

Authors:  Quan-guang Zhang; Dong Han; Rui-min Wang; Yan Dong; Fang Yang; Ratna K Vadlamudi; Darrell W Brann
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

7.  Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats.

Authors:  R B Gibbs
Journal:  Neurobiol Aging       Date:  2000 Jan-Feb       Impact factor: 4.673

8.  Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.

Authors:  R A Mulnard; C W Cotman; C Kawas; C H van Dyck; M Sano; R Doody; E Koss; E Pfeiffer; S Jin; A Gamst; M Grundman; R Thomas; L J Thal
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

9.  Estrogen-mediated neuroprotection after experimental stroke in male rats.

Authors:  T J Toung; R J Traystman; P D Hurn
Journal:  Stroke       Date:  1998-08       Impact factor: 7.914

10.  Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo.

Authors:  Jun Ming Wang; Ronald W Irwin; Roberta Diaz Brinton
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

View more
  1 in total

1.  A nationwide trend analysis in the incidence and mortality of Creutzfeldt-Jakob disease in Japan between 2005 and 2014.

Authors:  Yoshito Nishimura; Ko Harada; Toshihiro Koyama; Hideharu Hagiya; Fumio Otsuka
Journal:  Sci Rep       Date:  2020-09-23       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.